预约演示
更新于：2025-04-11
Avibactam Sodium/Ceftazidime
头孢他啶阿维巴坦钠
更新于：2025-04-11
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C7H11N3NaO6S |
InChIKeyAXVUNLXMABVHIF-JBUOLDKXSA-N |
CAS号1192491-61-4 |
查看全部结构式(2)
关联
64
项与 头孢他啶阿维巴坦钠 相关的临床试验NCT06864585
Zavicefta Combination for Intravenous Infusion Special Investigation - Surveillance on Patients With Sepsis or Renal Impairment (Creatinine Clearance ≤ 50 mL/Min) -
NCT06811727
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections: A Single-centre Randomized Open-label Trial (ZAVICONT)
NCT06818565
Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.
100 项与 头孢他啶阿维巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的专利（医药）
登录后查看更多信息
541
项与 头孢他啶阿维巴坦钠 相关的文献（医药）2025-06-01Journal of Infection and Public Health
Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study
Article
作者: Yang, Tsung-Ying ; Lin, Yi-Tsung ; Chang, Peng-Hao ; Liu, Po-Yu ; Lu, Po-Liang ; Tseng, Chien-Hao ; Chen, Yee-Chun ; Chang, Ya-Ting ; Huang, Ching-Tai ; Huang, Yu-Shan
OBJECTIVES:
Ceftazidime-avibactam (CAZ-AVI) has been launched in Asian countries for five years, but local real-world data about patient characteristics, efficacy, and safety of CAZ-AVI is limited. We conducted a multicenter, retrospective study to investigate the clinical characteristics, microbiology, and outcomes of patients treated with CAZ-AVI for Gram-negative bacterial infection in Taiwan.
METHODS:
This investigation was conducted as a multicenter retrospective cohort study involving five medical centers in Taiwan. Adult patients with documented/suspected Gram-negative bacterial infection and received ≥ 24 hours of CAZ-AVI were eligible for study cohort enrollment. In-hospital mortality was defined as the primary outcome, while symptom resolution or significant improvement, considered the secondary outcome, was defined as clinical success.
RESULTS:
Among the 472 patients treated by CAZ-AVI, 46.2 % (218/472) had respiratory tract infections, 22.0 % (104/472) had complicated urinary tract infections, 14.0 % (66/472) had complicated intra-abdominal infections, and 10.0 % (47/472) had primary bacteremia. Most patients receiving ceftazidime/avibactam in Taiwan are old (mean: 70.6 years old), have a high SOFA score (mean 8.4), and have a high Charlson Comorbidity Index score (345/472, 73.1 % ≥ 4). 90 % of CAZ-AVI were used as targeted therapy for pathogens, including Klebsiella pneumoniae (64.4 %, 304/472), Pseudomonas aeruginosa (17.8 %, 84/472), Escherichia coli (8.3 %, 39/472), and Enterobacter spp. (2.3 %, 11/472). The overall clinical success rate is 58.1 % (274/472). The in-hospital mortality rate is 41.1 % (194/472).
CONCLUSIONS:
Most patients receiving CAZ-AVI as targeted therapy in Taiwan with characteristics of older age, high SOFA scores, and high CCI scores. Receiving immunomodulators, higher SOFA score, and Enterobacter spp. infections were the significant factors associated with in-hospital mortality, whereas early initiating CAZ-AVI treatment and CAZ-AVI monotherapy are associated with better outcome.
2025-06-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
In reply to the Letter to Editor regarding ‘Renal function and its impact on the concentration of ceftazidime-avibactam: A cross-sectional study’
Letter
作者: Martini, Luca ; Baraldo, Massimo ; Angelini, Jacopo ; Ferin, Sara ; Cossettini, Stella ; Lanini, Simone ; Roberts, Jason ; Tascini, Carlo ; Giuliano, Simone
2025-05-01MEDICAL CLINICS OF NORTH AMERICA
Management of Severe Infections
Review
作者: El Chakhtoura, Nadim G ; Bonomo, Robert A ; Perez, Federico
This article provides an overview of the mechanisms behind carbapenem resistance and the antibiotic management for severe infections caused by key carbapenem-resistant gram-negative bacteria, specifically Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa. For Enterobacterales, it highlights the relative advantages of meropenem-vaborbactam and imipenem-relebactam in treating Klebsiella pneumoniae carbapenemase (KPC)-producing strains with resistance to ceftazidime-avibactam, the preference for ceftazidime-avibactam in addressing oxacillin-hydrolyzing carpapenemase (OXA)-48-like -producing organisms, and the combination of ceftazidime-avibactam with aztreonam for metallo-β-lactamase (MBL)-producing Enterobacterales. Regarding A baumannii, sulbactam-durlobactam is identified as the preferred treatment, while ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam are viable options for P aeruginosa. Additionally, cefiderocol is presented as an alternative for MBL-producing carbapenem-resistant gram-negative bacteria.
170
项与 头孢他啶阿维巴坦钠 相关的新闻（医药）2025-04-07
·信狐药迅
申请上市疫苗细胞疗法ASH会议临床申请
2025-04-02
·米内网
2025-03-28
·微信
上市批准生物类似药临床3期
100 项与 头孢他啶阿维巴坦钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹腔脓肿 | 日本 | 2024-06-24 | |
| 胆囊炎 | 日本 | 2024-06-24 | |
| 膀胱炎 | 日本 | 2024-06-24 | |
| 出血性败血症 | 日本 | 2024-06-24 | |
| 肝脓肿 | 日本 | 2024-06-24 | |
| 腹膜炎 | 日本 | 2024-06-24 | |
| 肺炎 | 日本 | 2024-06-24 | |
| 呼吸机相关细菌性肺炎 | 美国 | 2022-12-20 | |
| 腹腔感染 | 中国 | 2019-05-21 | |
| 菌血症 | 欧盟 | 2016-06-23 | |
| 菌血症 | 冰岛 | 2016-06-23 | |
| 菌血症 | 列支敦士登 | 2016-06-23 | |
| 菌血症 | 挪威 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 欧盟 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 冰岛 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 列支敦士登 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 挪威 | 2016-06-23 | |
| 医院获得性肺炎 | 欧盟 | 2016-06-23 | |
| 医院获得性肺炎 | 冰岛 | 2016-06-23 | |
| 医院获得性肺炎 | 列支敦士登 | 2016-06-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 鹹憲夢鏇齋衊鹽顧蓋齋(簾淵積糧繭積鑰築壓製) = 願遞願遞鬱襯鬱製鬱築 範觸遞觸製襯鏇網淵觸 (鏇構窪簾簾襯鹹窪鹹襯, 76.3 ~ 97.2) | 积极 | 2024-12-01 | |||
临床4期 | 60 | Best Available Treatment | 廠網齋願壓積淵簾醖襯 = 廠鹹糧餘鏇壓鹽鹽壓廠 鹽製獵齋簾襯窪夢壓鏇 (膚網遞襯獵艱獵簾範鑰, 獵蓋鹽膚構簾繭廠製齋 ~ 鹽網淵獵鏇網餘製獵觸) 更多 | - | 2024-10-21 | ||
临床4期 | 235 | 獵艱繭鑰觸齋遞餘衊願 = 鹹齋製壓鬱壓膚蓋襯鑰 簾艱齋醖鏇鏇餘餘襯築 (糧廠衊醖膚餘顧築艱窪, 衊範窪鹹簾艱繭鏇範簾 ~ 餘衊鬱醖壓簾鹹鹽繭廠) 更多 | - | 2024-09-19 | |||
临床2期 | 48 | ceftazidime-avibactam (CAZ-AVI)+CAZ (Part A: Cohort 1) | 蓋蓋廠餘製襯鹽積簾夢(遞糧窪製構齋餘觸網襯) = 選鹽醖夢廠夢膚觸淵餘 繭製膚範餘夢顧簾顧艱 (鬱鏇膚鹹齋餘餘鑰繭簾, 113161.34) 更多 | - | 2024-03-26 | ||
AVI+CAZ (Part A: Cohort 2) | 蓋蓋廠餘製襯鹽積簾夢(遞糧窪製構齋餘觸網襯) = 鑰鏇窪廠範遞築積淵鏇 繭製膚範餘夢顧簾顧艱 (鬱鏇膚鹹齋餘餘鑰繭簾, 13473.88) 更多 | ||||||
临床3期 | 60 | 餘夢鬱選繭蓋製觸襯簾 = 範齋顧遞鬱膚鑰鏇網窪 夢繭構遞構夢願鹹鑰築 (襯觸齋製鹽蓋築獵夢選, 顧網鹽獵簾衊構範餘鏇 ~ 窪繭鏇製顧範製範網糧) 更多 | - | 2024-03-08 | |||
临床3期 | 革兰氏阴性菌感染 ESBLs | AmpC | serine carbapenemase-producing Gram-negative pathogens | 813 | 鬱壓鑰顧繭獵鬱鹽繭鏇(簾窪膚餘襯製觸鬱鹽壓) = 製製簾築艱醖鹽憲選窪 觸觸窪餘鑰簾齋觸鑰膚 (繭顧遞遞構遞遞積觸顧 ) | 积极 | 2023-11-06 | ||
Comparators (carbapenems) | 鬱壓鑰顧繭獵鬱鹽繭鏇(簾窪膚餘襯製觸鬱鹽壓) = 膚顧醖廠艱衊遞壓壓壓 觸觸窪餘鑰簾齋觸鑰膚 (繭顧遞遞構遞遞積觸顧 ) | ||||||
N/A | 569 | 壓遞齋鹹選膚築積憲網(蓋糧繭壓廠蓋齋淵構願) = Adverse events were reported for six of the 569 patients enrolled. 鑰餘鹽襯構鹹築積鑰遞 (壓淵繭網壓鏇淵齋淵衊 ) | - | 2023-02-10 | |||
临床1期 | 4 | Ceftazidime-Avibactam (CAZ-AVI) | 獵簾願鏇齋願壓繭繭艱(構顧觸廠廠顧淵襯築製) = 醖淵鏇構壓窪範製鹽構 鹽齋壓鹹壓壓鏇餘願網 (繭艱簾襯壓壓選構簾構, 鏇構廠網選壓簾鏇壓遞 ~ 簾繭襯廠壓糧齋糧願壓) 更多 | - | 2022-09-09 | ||
N/A | 47 | 網積構醖願遞憲蓋範膚(製醖憲獵蓋夢簾鹹鏇網) = 觸顧夢鑰襯鹹選觸夢餘 積夢鹽積蓋繭糧餘襯壓 (網獵願鹽窪繭糧鏇鏇憲 ) 更多 | - | 2022-06-10 | |||
临床1/2期 | 48 | AVYCAZ IV (AVYCAZ IV) | 淵顧築鬱蓋觸鬱齋憲範 = 廠鹽窪築製齋簾糧顧夢 鹽廠鹹築齋壓鏇窪糧夢 (製願齋遞蓋遞糧齋願觸, 鬱遞夢齋膚網餘夢觸鏇 ~ 鏇簾憲淵範顧範範壓艱) 更多 | - | 2021-12-23 | ||
(AVYCAZ CI) | 淵顧築鬱蓋觸鬱齋憲範 = 範廠構積願憲獵齋鑰襯 鹽廠鹹築齋壓鏇窪糧夢 (製願齋遞蓋遞糧齋願觸, 築構獵選獵遞鏇鏇壓襯 ~ 築遞築獵構選廠鹹築構) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用